ADC Therapeutics to Host Second Quarter 2021 Financial Results Conference Call on August 3, 2021

Rhea-AI Summary

ADC Therapeutics (NYSE: ADCT) is set to host a conference call on August 3, 2021, at 8:30 a.m. EDT. The purpose is to discuss Q2 2021 financial results and share business updates. Investors can join via telephone or through a live webcast available on the company's website. ADC Therapeutics is focused on developing novel antibody drug conjugates for cancer treatment, with ZYNLONTA™ approved for certain lymphomas and ongoing trials for other therapies including Cami for Hodgkin lymphoma.

Positive

• ADC Therapeutics is hosting a significant conference call to discuss Q2 2021 financial results.
• ZYNLONTA™ is approved for treating relapsed or refractory diffuse large B-cell lymphoma, indicating strong market potential.
• Ongoing clinical trials, including Cami for Hodgkin lymphoma, suggest a robust pipeline for future growth.

Negative

• None.

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced that it will host a conference call and live webcast on Tuesday, August 3, 2021 at 8:30 a.m. EDT to report financial results for the second quarter 2021 and provide business updates.

To access the live call, please dial 833-303-1198 (domestic) or +1 914-987-7415 (international) and provide confirmation number 6962756. A live webcast of the presentation will be available under “Events and Presentations” in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of cancer patients with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics’ CD19-directed ADC ZYNLONTA™ (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a late-stage clinical trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, the Company has multiple PBD-based ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.

ZYNLONTA™ is a trademark of ADC Therapeutics SA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210728006046/en/

FAQ

What is the date and time of ADC Therapeutics' Q2 2021 earnings call?

The Q2 2021 earnings call for ADC Therapeutics is scheduled for August 3, 2021, at 8:30 a.m. EDT.

How can investors access the ADC Therapeutics earnings call?

Investors can access the earnings call by dialing 833-303-1198 domestically or +1 914-987-7415 internationally, using confirmation number 6962756.

What is ZYNLONTA™ and its significance for ADC Therapeutics?

ZYNLONTA™ is an FDA-approved drug for treating relapsed or refractory diffuse large B-cell lymphoma, highlighting ADC Therapeutics' advancement in targeted cancer therapies.

What other products is ADC Therapeutics developing?

ADC Therapeutics is also developing Cami for Hodgkin lymphoma and has multiple PBD-based ADCs in various stages of clinical and preclinical development.